Wondering...Any chance, if Roche/Genentech is keeping an eye on this puppy?
FYI:[Etrolizumab in clinical trials:
Etrolizumab (RG7413) is an investigational therapy to treat inflammatory bowel disease (IBD), being developed by Genentech to treat both ulcerative colitis (UC) and Crohn’s disease (CD).
It is currently in Phase 3 clinical trial as part of Genentech’s Etro Studies program, assessing its safety and efficacy in both UC and Crohn’s. During this trial, etrolizumab will be compared to other currently the U.S. Food and Drug Administration (FDA)-approved drugs, namely Remicade (infliximab) and Humira (adalimumab), and to placebo. There are five planned trials for patients with UC, and two for those with CD, to be carried out in the U.S., as well as one non-U.S. based trial in UC patients. All these studies are currently recruiting participants......]